Study of binding and neutralising antibodies to interferon-β in two groups of relapsing-remitting multiple sclerosis patients

Journal of Neurology

Volumn 248, Issue 5, 2001, Pages 383-388

  Fernández, Oscar ^a   Mayorga, Cristobalina ^a   Luque, Gloria ^a   Guerrero, Miguel ^a   Guerrero, Rocío ^a   Leyva, Laura ^a   León, Antonio ^a   Blanca, Miguel ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Interferon ; Multiple sclerosis; Neutralising antibodies

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; INTERFERON ANTIBODY; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY;

ADULT; ANTIBODY DETECTION; ANTIGEN BINDING; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOTHERAPY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RECURRENT DISEASE;

ADULT; ANTIBODY FORMATION; BIOLOGICAL RESPONSE MODIFIERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOSYLATION; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROSPECTIVE STUDIES; RECURRENCE;

EID: 0035012959     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004150170178     Document Type: Article

References (30)

1. Abdul-Ahad AK, Galazka AR, Revel M, Biffoni M, Borden EC (1997) Incidence of antibodies to interferon-β in patients treated with recombinant human interferon-β1 a from mammalian cells. Cytokines Cell Mol Ther 3:27-32
2. Andersson PB, Waubant E, Goodkin DE (1997) How should we proceed with disease-modifying treatments for multiple sclerosis? Lancet 349:586-587
3. Antonelli G, Bagnato F, Pozzilli C, Simeoni E, Bastianelli S, Currenti M, de Pisa F, Fieschi C, Gasperini C, Salvetti M, Dianzani F (1998) Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-β1a. J Interferon Cytokine Res 18:345-350
4. Antonelli G, Simeoni E, Bagnato F, Pozzilli C, Turriziani O, Tesoro R, Di Marco P, Gasperini C, Fieschi C, Dianzani F (1999) Further study on the specificity and incidence of neutralizing antibodies to Interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1 a or IFN beta-1b. J Neurol Sci 168:131-136
5. Arnason B (1997) Neutralising antibodies: are they an issue? Int MS J 4:40-42
6. Correale J, Gilmore W, McMillan M, Li S, McCarthy K, Le T, Weiner LP (1995) Patterns of cytokine secretion by autoreactive proteolipid protein-specific T cell clones during the course of multiple sclerosis. J Immunol 154:2959-2968
7. Deisenhammer F, Reindl M, Harvey J, Gasse T, Dilitz E, Berger T (1999) Bioavailability of Interferon beta 1 b in MS patients with and without neutralizing antibodies. Neurology 52:1239-1243
8. European Study Group on Interferon β-1 b in secondary progressive MS (1998) Placebo-controlled multicentre randomised trial of Interferon β-1 b in treatment of secondary progressive multiple sclerosis. Lancet 352:1491-1497
9. Fierlbeck G, Schreiner T (1994) Incidence and clinical significance of therapy-induced neutralizing antibodies against interferon-β. J Interferon Res 14:205-206
10. Hermans G, Stinissen P, Hauben L, Van den Berg-Loonen E, Raus J, Zhang J (1997) Cytokine profile of myelin basic protein-reactive T cells in multiple sclerosis and healthy individuals. Ann Neurol 42:18-27
11. Jacobs LD, Beck RW, Simon JH, et al. (2000) Intramuscular Interferon β-1 a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343:898-904
12. Jacobs LD, Cookfair DL, Rudick RA, Herndon R, et al (1996) Intramuscular Interferon beta-1 a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285-294
13. Kawade Y (1994) Quantitative determination of neutralization titers. Methods Enzymol 119:558-573
14. Kivisäkk P, Alm GV, Tian WZ, Matusevivius D, Fredriksen S, Link H (1997) Neutralising and binding anti-interferon β-1 b (IFNβ-1 b) antibodies during IFNβ-1 b treatment of multiple sclerosis. Mult Scler 3:184-190
15. Link H (1998) The cytokine storm in multiple sclerosis. Mult Scler 4:12-15
16. Maeyer-Guignard J de, de Maeyer E (1986) Natural antibodies to interferon-α and interferon-β are a common feature of inbred mouse strains. J Immunol 136:1708-1711
17. Mayorga C, Luque G, Romero F, Guerrero R, Blanca M, Fernandez O (1999) Antibodies to commercially available interferon-beta molecules in multiple sclerosis patients treated with natural interferon-beta. Int Arch Allergy Immunol 118:368-371
18. McKenna RM, Oberg KE (1997) Antibodies to interferon-alpha in treated cancer patients incidence and significance. J Interferon Cytokine Res 17:141-143
19. Pachner AR (1997) Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: Plight of the practising neurologist. Neurology 49:647-650
20. Poser CM, Paty DW, Scheinberg L, McDonald I, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberbeg DH, Tourtellotte WW (1983) New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 13:227-230
21. PRIMS. Prevention on Relapses and Disability by Interferon β-1 a Subcutaneously in Multiple Sclerosis (1998) Randomized double-blind placebo- controlled study of Interferon β-1 a in relapsing/remitting multiple sclerosis. Lancet 352:1498-1504
22. Redlich PN, Hoeprich PD, Colby CB, Grossberg SE (1991) Antibodies that neutralize human β-interferon biologic activity recognize a linear epitope: Analysis by synthetic peptide mapping. Proc Natl Acad Sci USA 88:4040-4044
23. Rice G, Paszner B, Oger J, Lesaux J, Paty D, Ebers G (1999) The evolution of neutralizing antibodies in multiple sclerosis patients treated with Interferon β-1b. Neurology 52:1277-1279
24. Rudick RA, Simonian JA, Alam JA, Campion M, Scaramucci JO, Jones W, Coats ME, Goodkin DE, Weinstock- Guttman B, Herndon RM, Mass MK, Richert JR, Salazar AM, Munschauer FE, Cookfair DL, Simon JH, Jacobs LD and the Multiple Sclerosis Collaborative Research Group (1998) Incidence and significance of neutralising antibodies to Interferon beta-1 a in multiple sclerosis. Neurology 50:1266-1272
25. Runkel L, Meier W, Pepinsky B, Karpusas M, Whitty A, Kimball K, Brickelmaier M, Muldowney C, Jones W, Goelz SE (1998) Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-β (IFN-β). Pharmacol Res 15:641-649
26. The IFN-β Multiple Sclerosis Study Group (1993) Interferon beta-1 b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655-661
27. The IFN-β Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1995) Interferon beta-1 b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 45:1277-1285
28. The IFN-β Multiple Sclerosis Study Group (1996) Neutralising antibodies during treatment of multiple sclerosis with Interferon beta-1 b: experience during the first three years. Neurology 47:889-894
29. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L (1998) Axonal transection in the lesions of multiple sclerosis.N Engl J Med 338:278-285
30. Wandinger KP, Reisslland P, Kirchner H, Wessel K, Otto M (1998) Production of endogenous interferon-alpha and beta in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 64:277-278